AR105711A1 - Compuestos de hidroxitriazina y sus usos farmacéuticos - Google Patents

Compuestos de hidroxitriazina y sus usos farmacéuticos

Info

Publication number
AR105711A1
AR105711A1 ARP160102503A ARP160102503A AR105711A1 AR 105711 A1 AR105711 A1 AR 105711A1 AR P160102503 A ARP160102503 A AR P160102503A AR P160102503 A ARP160102503 A AR P160102503A AR 105711 A1 AR105711 A1 AR 105711A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
formula
hydrogen
compound
Prior art date
Application number
ARP160102503A
Other languages
English (en)
Spanish (es)
Inventor
Yamashita Masaki
Hirono Yutaro
Mitani Ikuo
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AR105711A1 publication Critical patent/AR105711A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP160102503A 2015-08-17 2016-08-16 Compuestos de hidroxitriazina y sus usos farmacéuticos AR105711A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015160284 2015-08-17

Publications (1)

Publication Number Publication Date
AR105711A1 true AR105711A1 (es) 2017-11-01

Family

ID=58052084

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102503A AR105711A1 (es) 2015-08-17 2016-08-16 Compuestos de hidroxitriazina y sus usos farmacéuticos

Country Status (19)

Country Link
US (3) US20170057943A1 (https=)
EP (2) EP4046991A1 (https=)
JP (4) JP2017039714A (https=)
KR (1) KR20180037270A (https=)
CN (1) CN108137515B (https=)
AR (1) AR105711A1 (https=)
AU (1) AU2016309337B2 (https=)
BR (1) BR112018001809A2 (https=)
CA (1) CA2992410A1 (https=)
CL (1) CL2018000430A1 (https=)
CO (1) CO2018002516A2 (https=)
IL (1) IL257559B (https=)
MX (1) MX375283B (https=)
PE (1) PE20180951A1 (https=)
PH (1) PH12018500181A1 (https=)
SG (1) SG11201800698VA (https=)
TW (1) TWI704139B (https=)
WO (1) WO2017030115A1 (https=)
ZA (1) ZA201801134B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
PE20180951A1 (es) * 2015-08-17 2018-06-11 Japan Tobacco Inc Compuestos de hidroxitriazina y usos medicos de los mismos
US10710967B2 (en) * 2015-10-29 2020-07-14 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
RU2648181C1 (ru) * 2017-05-25 2018-03-22 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения нейроретинопатии вследствие тяжелой преэклампсии
WO2019002183A1 (de) * 2017-06-26 2019-01-03 Merck Patent Gmbh Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen
TW202409037A (zh) * 2022-07-06 2024-03-01 日商Aska製藥股份有限公司 嘧啶衍生物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473818A (de) 1964-03-18 1969-06-15 Ciba Geigy Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung
SU1313854A1 (ru) 1985-04-17 1987-05-30 Институт Органической Химии Ан Армсср Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина
DE19543730A1 (de) 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
ZA9710727B (en) 1996-12-05 1998-06-12 Amgen Inc Substituted pyrimidine compounds and methods of use.
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
AP2005003199A0 (en) 1999-04-01 2005-03-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
WO2008124092A2 (en) 2007-04-03 2008-10-16 E. I. Du Pont De Nemours And Company Substituted benzene fungicides
JP5388270B2 (ja) 2008-06-04 2014-01-15 株式会社Adeka 2,4,6−トリス(ヒドロキシフェニル)−1,3,5−トリアジン化合物の製造方法
EP2573076B1 (en) 2008-06-04 2014-08-20 Adeka Corporation Method for producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
AU2010298720B2 (en) 2009-09-23 2015-07-23 Albert Einstein College Of Medicine, Inc. Prostaglandin transporter inhibitors and uses thereof
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
AR086254A1 (es) * 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
JP2015522546A (ja) 2012-05-23 2015-08-06 ステマージ バイオテクノロジー エスエー ミトコンドリア電子伝達鎖の複合体(iii)の活性の阻害剤およびその使用
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) 2014-11-13 2016-05-18 东丽纤维研究所(中国)有限公司 一种拒水抗紫外纺织品及其生产方法和用途
PE20180951A1 (es) * 2015-08-17 2018-06-11 Japan Tobacco Inc Compuestos de hidroxitriazina y usos medicos de los mismos

Also Published As

Publication number Publication date
AU2016309337B2 (en) 2021-03-04
JP2017039714A (ja) 2017-02-23
US12492182B2 (en) 2025-12-09
US20240076278A1 (en) 2024-03-07
TW201718524A (zh) 2017-06-01
JP2024019449A (ja) 2024-02-09
RU2018109220A (ru) 2019-09-19
MX375283B (es) 2025-03-06
IL257559B (en) 2021-07-29
EP3339296A1 (en) 2018-06-27
CN108137515B (zh) 2021-07-06
IL257559A (en) 2018-04-30
ZA201801134B (en) 2019-07-31
CL2018000430A1 (es) 2018-08-03
SG11201800698VA (en) 2018-03-28
PH12018500181A1 (en) 2018-07-30
JP2020193235A (ja) 2020-12-03
RU2018109220A3 (https=) 2019-11-15
WO2017030115A1 (ja) 2017-02-23
US20210024486A1 (en) 2021-01-28
JP7640658B2 (ja) 2025-03-05
CO2018002516A2 (es) 2018-05-31
AU2016309337A1 (en) 2018-02-01
CA2992410A1 (en) 2017-02-23
JP2022163169A (ja) 2022-10-25
BR112018001809A2 (pt) 2018-09-18
CN108137515A (zh) 2018-06-08
EP4046991A1 (en) 2022-08-24
EP3339296A4 (en) 2019-01-23
US20170057943A1 (en) 2017-03-02
MX2018002044A (es) 2018-04-13
KR20180037270A (ko) 2018-04-11
PE20180951A1 (es) 2018-06-11
TWI704139B (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
AR105711A1 (es) Compuestos de hidroxitriazina y sus usos farmacéuticos
MX2016010875A (es) Compuesto de triazina y su uso para propositos medicos.
AR118856A2 (es) Compuestos terapéuticos
CY1123401T1 (el) Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
AR089768A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
AR094311A1 (es) Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
AR111314A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX376283B (es) Compuestos de imidazopiridazina.
MX374724B (es) Derivados de carbazol.
AR114420A1 (es) Derivados de 2,4-diaminoquinazolina y usos médicos de los mismos
UY36124A (es) Derivados de carboxamida
EA201692298A1 (ru) Производные карбоксамидов
AR097754A1 (es) Derivados sustituidos de fenilalanina
MX2022000154A (es) Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos.
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
AR102208A1 (es) Compuestos de isotiazolo tiazina inhibidores de bace1
AR101766A1 (es) Compuesto para la inhibición de indolamina-2,3-dioxigenasa
AR099678A1 (es) Heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis
CU20160170A7 (es) Derivados de carboxamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure